Are You Prepared for the New Wave of ADCs in NSCLC? Targeting HER2, HER3, TROP2, and Others PeerView Oncology 56:23 1 year ago 5 278 Скачать Далее
Combining ADCs with other treatment modalities in NSCLC VJOncology 1:47 9 months ago 45 Скачать Далее
Reshaping the Future of Lung Cancer Treatment With TROP2-Targeting ADCs and Rational Combinations PeerView Oncology 49:56 9 months ago 841 Скачать Далее
Answers to Key Questions About Antibody–Drug Conjugates in NSCLC PeerView Oncology 1:00:29 1 year ago 467 Скачать Далее
Is ADC the answer to lung cancer #2023 #oncology #lungcancer OncBrothers: Practice-Changing Cancer Discussions 0:59 10 months ago 1 804 Скачать Далее
2021 West Oncology | Lung Cancer | EGFR Mutation Therapy Resistance and ADCs and TROP2 Total Health | Oncology 20:34 3 years ago 2 077 Скачать Далее
Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted Therapies PeerView Oncology 58:27 2 years ago 1 355 Скачать Далее
Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology Conference Total Health | Oncology 27:03 1 year ago 11 645 Скачать Далее
Emerging second-line treatment approaches in advanced NSCLC: The role of ADCs Touch Medical Media Services 34:17 5 months ago 99 Скачать Далее
Amplifying the ADC Advantage: ADCs as the Next Frontier in Precision Lung Cancer Care PeerView Oncology 1:37:33 1 year ago 1 651 Скачать Далее
